cover
Article Per Year (5 Year)
All
Home Page
OAI Link
Editorial Team
Contact
Reviewer
Google Scholar
Contact Name
Murdani Abdullah
Contact Email
ina.jghe@gmail.com
Phone
+6285891498517
Journal Mail Official
ina.jghe@gmail.com
Editorial Address
Divisi Gastroenterologi, Departemen Ilmu Penyakit Dalam, FKUI/RSUPN Dr. Cipto Mangunkusumo, Jl. Diponegoro No. 71 Jakarta 10430 Indonesia
Location
Kota adm. jakarta pusat,
Dki jakarta
INDONESIA
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy
Published by The Indonesian Society for Digestive Endoscopy
ISSN : 14114801     EISSN : 23028181     DOI : -
Core Subject : Health,
Medicine & Pharmacology
The Indonesian Journal of Gastroenterology, Hepatology and Digestive Endoscopy is an academic journal which has been published since 2000 and owned by 3 Societies: The Indonesian Society of Gastroenterology; Indonesian Association for the Study of the Liver; The Indonesian Society for Digestive Endoscopy. The aim of our journal is to advance knowledge in Gastroenterology, Hepatology, and Digestive Endoscopy fields. We welcome authors for original articles, review articles, and case reports in the fields of Gastroenterology, Hepatology, and Digestive Endoscopy.
Arjuna Subject : Kedokteran - Ilmu Pencernaan
Articles 771 Documents
 3   4   5   6   7 
Gastrointestinal Amyloidosis: Diagnostic Approach and Treatment Catarina Budyono; Achmad Fauzi; Dadang Makmun
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (321.691 KB) | DOI: 10.24871/1632015172-178

Abstract

Amyloidosis is a disease marked by deposition of misfolded proteins, known as amyloids, in the extracellular space, including gastrointestinal tract. According to the precursor protein, amyloidosis is classified into six types; all of which can be involved in the gastrointestinal tract. Amyloidosis has weight loss and gastrointestinal bleeding as the most frequent symptoms. Gastrointestinal tract biopsy is diagnostic in most cases of amyloidosis and Congo red stain is used to confirm the amyloid proteins deposit. Treatment of amyloidosis consists of controlling symptoms, terminating protein formation and deposit, and treating the underlying diseases. Chemotherapy might be applied depends on the type of amyloidosis. 
Correlation Between Fibrosis-4 (FIB-4) Score and Metavir Score of Chronic Hepatitis C (CHC) Patients in Saiful Anwar Hospital Malang Ekamaya Sofa Irawati; Bogi Pratomo
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (425.836 KB) | DOI: 10.24871/201201923-26

Abstract

Background: Hepatitis C still remain a serious problem in Indonesia lead to increasing prevalence , major morbidity and mortality. Liver biopsy is gold standar, invasive procedure for liver fibrosis staging for treatment monitoring and fibrosis regression. Fibrosis-4 (FIB-4) score has been proposed as a non-invasive, easy, inexpensive as alternative indirect marker for the assessment of liver fibrosis in chronic hepatitis C (CHC).Method: Analytical cross sectional study was conducted among 54 patients with CHC from 2012 -2017 in Saiful Anwar Hospital Malang. Subjects were examined for complete blood count, aspartate aminotransferase (AST), alanine aminotransferase (ALT), anti hepatitis C virus (anti HCV), hepatitis C virus ribonucleic acid (HCV RNA), genotype, and performed liver biopsy. Statistical analysis was performed using Spearman test and statistical significant was assumed when p 0,05.Results: Fifty four (54) patients were fulfilled the selection criteria from total 67 patients. 29 (53%) males, and 25 (47%) were females. The characteristic were 33 (61%) genotype 1, 12 (22%) genotype 2, 5 (9%) genotype 3, and undetermined 3 (6%); with means of  HCV RNA titer 2,57 x 106, AST 79 ± 44 IU/L, ALT 77 ± 48 IU/L platelet 160.000/mm3. Distribution of Metavir F1 10 (19%) ,  Metavir F2 31(57%), Metavir F3  6(11%), and Metavir F4 7 (13%). Median of FIB-4 score as Metavir F1 1,88;Metavir F2 3,24; Metavir F3 5,36; Metavir F4 4,36. There was positive correlation between FIB-4 score and Metavir score (r = 0.38; p = 0,01).Conclusion: This study indicate that there was significant correlation between FIB-4 score and Metavir score in CHC patients.
Optimum treatment regimens for Helicobacter pylori infection Richard H Hunt
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 1, NUMBER 1, December 2000
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/112000%p

Abstract

The treatment of Helicobacter pylori infection includes of current standard triple therapies consisting of a proton pump inhibitor, clarithromycin and amoxicillin or metronidazole on the basis of simplicity, safety, and efficacy. There are several factors determining the success of H. pylori eradication treatment. They include the components of a treatment regimen, the treatment duration, patient compliance, the presence of resistant or virulent strains of Helicobacter pylori and possibly the patient’s gastric acid secretory status. PPI, clarithromycin 500 mg, amoxicillin 1 g or metronidazol 400 mg, all given bid for 7 days are the most commonly used combination regimens. RBC-based triple therapies, furazolidone or rifabutin containing regimens can be used as an alternative approach to PPI-based triple therapies in areas where bacterial resistant strains of H. pylory are concerned.  Keywords: treatment, Helicobacter pylori, PPI,  clarithromycin, amoxicillin, metronidazole, PAM, PMC,  PAC, RBC
Helicobacter pylori Infection in Superficial Gastritis, Erosive Gastritis and Gastric Ulcer Jacobus Albertus; Abdul Aziz Rani; Marcellus Simadibrata; Murdani Abdullah; Ari Fahrial Syam
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 13, NUMBER 2, August 2012
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (687.24 KB) | DOI: 10.24871/132201274-79

Abstract

Background: Helicobacter pylori (H. pylori) infection leads to inflammation of the gastric mucosa. It damages the gastric epithelium and related to the risk of developing gastric cancer. Over time, it may develop into the development of glandular atrophy and intestinal metaplasia. This study was aimed to evaluate the histological features of gastric mucosa, including H. pylori infection in patients with endoscopically found superficial gastritis, erosive gastritis and gastric ulcer. Method: Subjects with abdominal complaints who underwent consecutive upper gastrointestinal endoscopy were prospectively selected at Tugurejo Hospital between November 2004 and December 2010. Eligible subjects were those with endoscopic diagnosis of superficial gastritis, erosive gastritis or gastric ulcer. The biopsy specimens were taken from the corpus, angulus and antrum of all the patients. Giemsa and hematoxylin-eosin staining were used for the histological diagnosis H. pylori and gastric mucosa inflammation. Results: The overall prevalence of H. pylori infection in superficial gastritis, erosive gastritis and gastric ulcer were 24.3%. There was significant difference between H. pylori infection rate in antrum of patients with superficial gastritis 19.4%, erosive gastritis 26.3%, and gastric ulcer 34.7%. The positivity rate of glandular atrophy and intestinal metaplasia of superficial gastritis with H. pylori- positivity was 12.5%, 14.0%; erosive gastritis 26.3%, 16.6%; and of gastric ulcer 38.9%, 29.3%; respectively. However, there was no significant difference. Conclusion: Patients with gastric ulcer have H. pylori infection, atrophic gastritis and metaplasia intestinal more than superficial gastritis and erosive gastritis. Progression of the gastric ulcer to atrophic gastritis and intestinal metaplasia is related to H. pylori infection. Keywords: Helicobacter pylori infection, superficial gastritis, erosion and ulcer
Clinical Practice in Intermediate Hepatocellular Carcinoma in the Real World Jasirwan, Chyntia Olivia Maurine
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (228.056 KB) | DOI: 10.24871/23120221-2

Abstract

-
Clinical Improvement of Dyspepsia Symptoms Following Eradication Treatment for Helicobacter pylori Khaira Utia Yusrie; Ari Fahrial Syam
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 7, ISSUE 3, December 2006
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/73200672-78

Abstract

The prevalence of Helicobacter pylori in patients with peptic ulcer in Indonesia is very high. It ranges between 90-100%. In general, patients with gastritis and peptic ulcer usually have dyspepsia symptoms. The pathophysiology of dyspepsia symptoms caused by Helicobacter pylori has not been clearly understood. However, it is assumed that the symptoms are correlated to various factors including inflammation, apoptosis damage, and increased secretion of gastric acid, atrophy and non-atrophy gastritis as well as the development of peptic ulcer. The main objective of treatment for Helicobacter pylori infection is elimination of Helicobacter pylori bacteria. Triple therapy has 80% success rate with no significant adverse events and minimal effect in inducing resistance to antibiotics. The success rate of eradication treatment in patients with peptic ulcer is 90%; while an evaluation on improvement of duodenal ulcus following eradication treatment with one month proton pump inhibitor treatment reveals 90% success rate. Keywords: Helicobacter pylori, improvement, dispepsia
Screening and Management of Colon Polyp as Colorectal Cancer Prevention Gratcia Ayundini; Marcellus Simadibrata
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (163.984 KB) | DOI: 10.24871/1722016112-115

Abstract

Colon polyp is a term used for abnormality from bulging tissue above surrounding colonic mucosal layer. Adenoma polyp was the commonly found polyp that progress to colorectal cancer. Most of those patients was asymptomatic. Undetected and unmanaged polyp was a risk factors of colorectal cancer event. 
Propofol Sedation in Diagnostic Upper Gastrointestinal Endoscopy Christophorus Simadibrata; Benvenuto Axel; Syahrizal Syahrizal; Dina Ikawari; Paulus Simadibrata; Marcellus Simadibrata
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (89.446 KB) | DOI: 10.24871/21120203-6

Abstract

Background: Sedation are commonly used these days in patients that having gastrointestinal endoscopy. Propofol is sedative  agent  that  commonly  used  in  endoscopy procedure.Method: All   patients   who   were   performed   diagnostic   EGD   in   Abdi   Waluyo   Hospital’s Gastrointestinal Endoscopy Unit from January 1st   2017 – 31st   December 2017, included in this study. The amount of Propofol, duration during hypnosis/sedation and adverse effects were all recorded.Results: 170  patients  were  performed  diagnostic  EGD  with  Propofol  sedation,  most  of them were male (87 patients, 51,5%). The median age was 48,78 + 14. The median Body Mass Index  (BMI)  was  24.45.  The median of duration of hynosis (sedation) during EGD was 5 minutes. The median of propofol total dose during EGD was 180 mg. Adverse effects that found during Propofol sedation are muscle twitching(10.6% patients) and pain in area of  injection(80% patients). Conclusion: The duration of propofol hypnosis/sedation during Esophagogastroduodenoscopy examination was 5 minutes. Propofol total dose needed for diagnostic EGD was 180 mg. The common adverse effects of propofol are muscle twitching and pain in area of injection.
The Diagnostic and Management of Drug Induced Esophagitis Alkindi Bahar; Ari Fahrial Syam; Chudahman Manan
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 3, NUMBER 3, December 2002
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.24871/33200286-90

Abstract

There are several factors that involve in drug induced esophagitis such as: drugs, esophagus, patients. The drug can cause direct effect to the esophageal mucosa. The drugs that often cause esphagitis: alendronate, tetracycline and its derivates and anti retroviral agents. Most of these drugs can cause esophageal damage due to corrosive nature of the drug. Esophageal factor that can cause the drug induced esophagitis: rheumatic heart disease, enlargement of the left atrium mass and aortal aneorysma. These conditions will disturb drug passage and prolongs drug contact with esophageal mucosa. The patients factor that influences this problem is the patients position when taking the drug, the patients age, the amount of water taken along with the drug, the time when drug was taken, and the amount of saliva. Endoscopy is a good procedure to evaluate the esophageal mucosa and establishing differential diagnosis through direct inspection, biopsy. In the management of esophagitis, PPIs are currently the most effectiveness agents available for treating esophagitis. Esomeprazole, an optical isomer of omeprazole is the first PPI to show greater efficacy than other PPI is in esophagitis healing.   Keywords: Esophagitis, drug induced, proton pump inhibitor.
Liver Disorders in Type 2 Diabetes Mellitus Suzanna Ndraha; Marshell Tendean; Fendra Wician; Henny Tanadi Tan; Helena Yap
The Indonesian Journal of Gastroenterology, Hepatology, and Digestive Endoscopy VOLUME 14, NUMBER 3, December 2013
Publisher : The Indonesian Society for Digestive Endoscopy

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (534.278 KB) | DOI: 10.24871/1432013154-157

Abstract

Background: Patients with type 2 diabetes mellitus (T2DM) are frequently diagnosed with some abnormal liver features. These liver abnormalities are suggested to be correlated with insulin resistance. The aim of thisstudy was to evaluate liver abnormalities and fasting insulin levels in patients with T2DM.Method: This study was conducted in Koja Hospital from February to July 2013. Study design was analytical study. Data for sex, age, complication, body mass index (BMI), liver function, liver enzyme, and fasting insulinlevel were collected. Univariate and bivariate statistical analyses were done using SPSS 20.Results: Twenty eight patients were included in this study, 71.43% of them were female. The age group of 40-60 years was the highest among the patients (64.28%). Highest complication was neuropathy, BMI of mostpatients were obese. Liver abnormalities were documented in 35.8% patients, liver enzyme increased in 21.4% patients. Non alcoholic fatty liver disease (NAFLD) were noted in 46.6% patients, and one patient was positive for hepatitis B. Mean fasting insulin in T2DM with NAFLD were higher than in T2DM without NAFLD. However, it was not statistically significant (40.08 ± 36.8 μU/mL vs. 54.3 ± 37.1 μU/mL; p = 0.27).Conclusion: Liver abnormalities found in T2DM patients were elevated liver enzyme, decreased albumin and increased of bilirubin. Through ultrasound, NAFLD and liver cirrhosis were found. Fasting insulin levelwas higher in T2DM with NAFLD but it was not statistically significant.Keywords: type 2 diabetes mellitus, non alcoholic steato-hepatitis, fasting insulin

Page 5 of 78 | Total Record : 771

 3   4   5   6   7 

Filter by Year

2000 2025


Reset
Filter By Issues
All Issue Vol 26, No 2 (2025): VOLUME 26, NUMBER 2, AGUSTUS, 2025 Vol 26, No 1 (2025): VOLUME 26, NUMBER 1, April, 2025 Vol 25, No 3 (2024): VOLUME 25, NUMBER 3, December, 2024 Vol 25, No 2 (2024): VOLUME 25, NUMBER 2, August, 2024 Vol 25, No 1 (2024): VOLUME 25, NUMBER 1, April, 2024 Vol 24, No 3 (2023): VOLUME 24, NUMBER 3, December, 2023 Vol 24, No 2 (2023): VOLUME 24, NUMBER 2, August, 2023 Vol 24, No 1 (2023): VOLUME 24, NUMBER 1, April, 2023 Vol 23, No 3 (2022): VOLUME 23, NUMBER 3, December 2022 Vol 23, No 2 (2022): VOLUME 23, NUMBER 2, August 2022 Vol 23, No 1 (2022): VOLUME 23, NUMBER 1, April 2022 Vol 22, No 3 (2021): VOLUME 22, NUMBER 3, December 2021 Vol 22, No 2 (2021): VOLUME 22, NUMBER 2, August 2021 Vol 22, No 1 (2021): VOLUME 22, NUMBER 1, April 2021 Vol 21, No 3 (2020): VOLUME 21, NUMBER 3, December 2020 Vol 21, No 2 (2020): VOLUME 21, NUMBER 2, August 2020 Vol 21, No 1 (2020): VOLUME 21, NUMBER 1, April 2020 Vol 20, No 3 (2019): VOLUME 20, NUMBER 3, December 2019 Vol 20, No 2 (2019): VOLUME 20, NUMBER 2, August 2019 Vol 20, No 1 (2019): VOLUME 20, NUMBER 1, April 2019 Vol 19, No 3 (2018): VOLUME 19, NUMBER 3, December 2018 Vol 19, No 2 (2018): VOLUME 19, NUMBER 2, August 2018 Vol 19, No 1 (2018): VOLUME 19, NUMBER 1, April 2018 Vol 18, No 3 (2017): VOLUME 18, NUMBER 3, DECEMBER 2017 Vol 18, No 2 (2017): VOLUME 18, NUMBER 2, AUGUST 2017 Vol 18, No 1 (2017): VOLUME 18, NUMBER 1, April 2017 Vol 17, No 3 (2016): VOLUME 17, NUMBER 3, December 2016 Vol 17, No 2 (2016): VOLUME 17, NUMBER 2, August 2016 Vol 17, No 1 (2016): VOLUME 17, NUMBER 1, April 2016 Vol 16, No 3 (2015): VOLUME 16, NUMBER 3, December 2015 Vol 16, No 2 (2015): VOLUME 16, NUMBER 2, August 2015 Vol 16, No 1 (2015): VOLUME 16, NUMBER 1, April 2015 Vol 15, No 3 (2014): VOLUME 15, NUMBER 3, December 2014 Vol 15, No 2 (2014): VOLUME 15, NUMBER 2, August 2014 Vol 15, No 1 (2014): VOLUME 15, NUMBER 1, April 2014 VOLUME 14, NUMBER 3, December 2013 VOLUME 14, NUMBER 2, August 2013 VOLUME 14, NUMBER 1, April 2013 VOLUME 13, NUMBER 3, Desember 2012 VOLUME 13, NUMBER 2, August 2012 VOLUME 13, NUMBER 1, April 2012 VOLUME 12, NUMBER 3, December 2011 VOLUME 12, NUMBER 2, August 2011 VOLUME 12, NUMBER 1, April 2011 VOLUME 11, NUMBER 3, December 2010 VOLUME 11, NUMBER 2, August 2010 VOLUME 11, NUMBER 1, April 2010 VOLUME 10, NUMBER 3, December 2009 VOLUME 10, ISSUE 2, August 2009 VOLUME 10, ISSUE 1, April 2009 VOLUME 9, ISSUE 3, December 2008 VOLUME 9, ISSUE 2, August 2008 VOLUME 9, ISSUE 1, April 2008 VOLUME 8, ISSUE 3, December 2007 VOLUME 8 ISSUE 2 August 2007 VOLUME 8, ISSUE 1, April 2007 VOLUME 7, ISSUE 3, December 2006 VOLUME 7, ISSUE 2, August 2006 VOLUME 7, ISSUE 1, April 2006 VOLUME 6, ISSUE 3, December 2005 VOLUME 6, ISSUE 2, August 2005 VOLUME 6, ISSUE 1, April 2005 VOLUME 5, ISSUE 3, December 2004 VOLUME 5, ISSUE 2, August 2004 VOLUME 5, ISSUE 1, April 2004 VOLUME 4, ISSUE 3, December 2003 VOLUME 4, ISSUE 2, August 2003 VOLUME 4, NUMBER 1, April 2003 VOLUME 3, NUMBER 3, December 2002 VOLUME 3, NUMBER 2, August 2002 VOLUME 3, NUMBER 1, April 2002 VOLUME 2, NUMBER 3, December 2001 VOLUME 2, NUMBER 2, August 2001 VOLUME 2, NUMBER 1, April 2001 VOLUME 1, NUMBER 1, December 2000 More Issue